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The objective of this study was to compare four procedures for Chlamydia pneumoniae
DNA extraction from vascular tissue. The NucliSens Kit, the QIAamp tissue DNA
MiniKit, buffer-saturated phenol and the Geneclean II Kit were evaluated, based on
the yield of recovered DNA, using PCR to detect C. pneumoniae in vascular tissue. The
QIAamp tissue procedure had the highest detection level (0.004 inclusion-forming units/
sample). All methods, except NucliSens (70 min), had a short handling time (30–40 min).
Costs varied from 0.5 to 3.2 Euro.
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I N T R O D U C T I O N
Chlamydia pneumoniae has been associated with
atherosclerosis, initially on the basis of seroepi-
demiologic studies [1,2]. Two recent studies,
however, have failed to demonstrate any such
connection [3,4]. Subsequently, further evidence
has been provided by the detection of C. pneumo-
niae in atherosclerotic tissue by polymerase chain
reaction (PCR), immunocytochemistry [5–7], and
isolation in culture. Whether C. pneumoniae plays a
role in the pathogenesis of atherosclerosis is still
not known. Although serologic assays are consid-
ered the reference diagnostic method for C. pneu-
moniae infections, PCR is potentially an important
tool for further studies in this field. C. pneumoniae
PCR is, however, not yet standardized. Several
PCR assays have been used to detect C. pneumoniae
in vascular tissues. However, a considerable var-
iation in the detection rate of C. pneumoniae, ran-
ging from 0% to 100%, has been reported by
different investigators [5–10]. This phenomenon
can be explained by the differences between the
populations studied, by sampling error, and by
differences in the PCR techniques applied. The
potential for differences in performance between
PCR techniques is well known. For example, the
sensitivity of PCR for the detection of Mycobacter-
ium tuberculosis in samples containing low num-
bers of microorganisms varied among seven
laboratories from 2% to 90% [11]. A multicenter
study showed major inter-laboratory differences
in the detection rate of C. pneumoniae in endarter-
ectomy specimens [12]. Therefore, it is important
to determine a more standardized procedure that
includes DNA extraction from specimens. In order
to detect C. pneumoniae by PCR, efficient release of
C. pneumoniae DNA from vascular tissue and ade-
quate removal of PCR inhibitors (lipids and calci-
fication) are essential [13]. The purpose of this
study is to compare four procedures for C. pneu-
moniae DNA extraction from vascular tissue.
M A T E R I A L S A N D M E T H O D S
Vascular samples were obtained from 30 patients
during cardiac surgery (coronary artery bypass
graft—CABG). During this procedure, a punch
biopsy through the aortic wall is routinely taken.
This biopsy material was stored at 4 8C in 200 mL of
lysis buffer (1 M Tris, pH 7.0, 0.5 mM EDTA, 5 M
NaCl, 1% sodium docecyl sulfate (SDS), 20 mg/
mL proteinase K) for a maximum of 24 h. Subse-
quently, the sample was lyzed by adding 20 mL of
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proteinase K (20 mg/mL, Qiagen, Hilden, Ger-
many) and incubating overnight at 56 8C. After
cell lysis, a homogeneous solution was made by
pooling all 30 lysates. Seven 900-mL portions of the
homogenate were inoculated with decreasing con-
centrations of inclusion-forming units (IFUs) of C.
pneumoniae strain TW 183. Portion number 8, con-
taining AE buffer (QIAamp, Qiagen), was used as
a negative control.
Two hundred and five microliters of each por-
tion (corresponding to the concentrations of the
dilution series (10- and 5-fold): 10 000, 1000, 100,
10, and 2, 0.4, 0.08 IFU per 205 mL; per PCR (this is
500, 50, 5, 0.5, 0.1, 0.02 and 0.004 IFU) was sub-
jected to each of four methods of DNA extraction.
In the first procedure NucliSens (Organon
Teknika, Boxtel, The Netherlands) used, based
on the method of Boom et al. [14], according to
the manufacturer’s instructions. This technique is
based on the mechanism whereby DNA binds to
glass particles (silica) in a high concentration of
chaotropic salt, while contaminants such as pro-
teins, carbohydrates and ions do not. A wash
procedure is repeated three times to remove all
contaminants (with wash buffer, or 70% ethanol or
acetone). DNA is eluted from the silica by resus-
pension of the silica complexes in NucliSens elu-
tion buffer.
In the second procedure the QIAamp DNA
MiniKit (Qiagen) was used, according to the
QIAamp tissue protocol in the manufacturer’s
instructions. This method uses a QIAamp spin
column to which DNA binds in the presence of
buffer AL and ethanol. Two wash steps, in which
AW1 buffer and AW2 buffer succeed each other,
are performed to remove contaminants. AE buffer
is finally used for elution of the DNA from the spin
column.
In the third procedure buffer-saturated phenol
(Life Technologies, Breda, the Netherlands) was
used. This method is home-made, based on ‘clas-
sical’ phenol extraction. In this method, 200 mL of
buffer-saturated phenol (pH 7.5–7.8) was added to
205 mL of sample in a 1.5-mL screw-cap plastic
tube, vortexed for 1 min, and centrifuged for
5 min at 20 000 g. The aqueous supernatant was
transferred to another tube, which also contained
200 mL of buffer-saturated phenol. After homoge-
nizing and centrifuging (5 min at 20 000 g), the
aqueous supernatant was transferred to a 1.5-
mL screw-cap plastic tube containing 20 mL of
3 M sodium acetate (pH 5.2) and vortexed. Ice-cold
absolute ethanol (440 mL) was added, and the
mixture was homogenized and incubated at
20 8C for 15 min The sample was centrifuged
(15 min, 20 000 g) to pellet the DNA products.
The supernatant was removed, and the pellet
resuspended in 250 mL of 70% ethanol, vortexed
and centrifuged for 5 min (20 000 g). The super-
natant was removed again, and a quick centrifuge
spin was done, so that the remaining ethanol could
be removed. The pellet was air-dried in a half-open
tube and suspended in 100 mL of AE buffer by
vortexing.
In the fourth procedure the Geneclean II Kit
(Qbiogene, Illkirch, France) was used, according
to the manufacturer’s instructions. Like the first
method, this method is also based on the fact that
DNA binds to glass particles in a high concentra-
tion of chaotropic salt. Here, the DNA binds to
Glassmilk. The Glassmilk–DNA pellet is washed
once with New Wash.
All DNA elutions (in 100 mL of AE buffer, (Qia-
gen)) were resuspended at 80 8C for 5 min, which
completed the DNA extraction.
An identical PCR assay was performed on 5 mL
of each sample to detect C. pneumoniae DNA,
irrespective of extraction method. All amplifica-
tion steps, assay conditions, signals, visualization
steps and hybridization procedures were identical.
Polymerase chain reaction
Primers CpnA (50-TGA CAA CTG TAG AAA TA-
C AGC-30) and CpnB (50-CGC CTC TCT CCT A-
TA AAT-30) were used in a PCR based on the
16S rRNA gene sequence as described by Gaydos
et al. [15].
The PCR reaction mixture contained 30 pmol of
each primer, 3 mM MgCl2, 200 mM dNTPs (dTTP is
replaced by dUTP), 2.5 units of AmpliTaq Gold
DNA polymerase (Perkin Elmer Cetus, Norwalk,
Conn., USA), 10PCR buffer II (Perkin Elmer),
and 1.25 mL of internal control.
An internal control was added in each reaction
to enable detection of inhibition of the PCR reac-
tion and prevent false-negative PCR results. The
internal control template DNA consisted of a PCR
product of an unknown fragment of Escherichia coli
DNA that yields a 150-bp PCR product in combi-
nation with primer PINTK (50-(ACTG 4)-AC-30).
The PCR amplification was performed as fol-
lows: after addition of 5 mL of template DNA in a
final volume of 25 mL of PCR reaction mixture,
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samples were subjected to the following PCR pro-
gram: 10 min at 96 8C, followed by 40 cycles of 30 s
at 95 8C, 30 s at 55 8C, and 1 min at 72 8C. A final
step of 10 min at 72 8C completed the PCR in a
thermocycler (9600, Perkin Elmer). A negative
PCR mix control and a negative sample-processing
control were included in each PCR run with every
five samples to detect false-positive results.
For final product detection, amplification pro-
ducts were examined by agarose gel electrophor-
esis and dot-blot hybridization as follows. Eight
microliters of each PCR product was analyzed by
agarose gel electrophoresis on 2% agarose gels in
TBE buffer containing ethidium bromide. PCR
products were visualized under UV transillumi-
nation and photographed. If the 450-bp Chlamydia-
derived band was visible (with or without the 150-
bp band), the sample was considered positive. If
only the 150-bp band of the internal control was
visible, the sample was considered negative. If no
bands were visible, the PCR was considered inhib-
ited, and the sample was repurified and retested
by PCR.
Dot-blot hybridization
Hybridization of 5 mL of the PCR products was
performed using a 50-biotinylated C. pneumoniae-
specific probe, Cpneu-B: 50-ACACACGTGCTA-
CAATGGTT-30. Hybridization signals were visua-
lized using streptavidin peroxidase (Boehringer
Mannheim, Mannheim, Germany) and ECL detec-
tion reagents (Amersham, Biosciences UK Lim-
ited, Little Chatfont, UK).
To minimize the risk of contamination, sample
preparation, PCR amplification and analysis of the
PCR product were performed in separate rooms.
Analysis
Comparison of the four procedures was done
using gel electrophoresis and dot-blot hybridiza-
tion. Each procedure was also compared for over-
all time consumption and hands-on time per sam-
ple. Hands-on time was defined as time needed by
the technician working with this procedure, and
overall time as the total time, including centrifu-
ging, incubation, etc. Finally, the average costs per
sample were estimated in Euros, calculated from
the price of the commercial kit and material (e.g.
ethanol), excluding the use of materials such as
plastic tubes, divided by the number of samples.
R E S U L T S
Figure 1 shows the results of C. pneumoniae detec-
tion for each method. The detection levels ranged
from 0.004 IFU per sample for QIAamp, to 0.1 IFU
per sample for phenol extraction and NucliSens,
and 0.5 IFU per sample for Geneclean II (Table 1).
Table 1 DNA extraction methods












NucliSens 0.1 70 115 3.2
QIAamp 0.004 35 60 2.9
Phenol 0.1 40 105 0.5
Geneclean II 0.5 30 60 1.4
Figure 1 Agarose gel electrophoresis of PCR products
(Chlamydia pneumoniae) using four DNA extraction
methods.
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The least labor-intensive method was the Gene-
clean II, with a hands-on time of 30 min, and an
overall time of 60 min (Table 1). Costs per sample
for various methods show that buffer-saturated
phenol was the cheapest method, with an average
of 0.5 Euro per sample (Table 1).
D I S C U S S I O N
In this study, we compared four different DNA
extraction methods. To create realistic study mate-
rial, a homogenate solution was prepared from
aorta tissue samples inoculated with IFUs from C.
pneumoniae. The QIAamp DNA MiniKit extraction
method detected the lowest amount of IFUs by far.
Also, it is a rapid and easy-to-perform procedure.
The associated costs represent a disadvantage.
Several factors influence the ability of PCR to
detect C. pneumoniae, including sample prepara-
tion, DNA extraction, amplification assays, and
visualization procedures. Standardization of these
factors was therefore approached in the present
study.
Because C. pneumoniae is an intracellular patho-
gen, vascular tissue was treated with proteinase K
to produce tissue cell lysis and release C. pneu-
moniae DNA, if present. The aorta samples used
in the present study were macroscopically non-
atherosclerotic, and the expected positivity rate
was low [16]. Since the amount of C. pneumoniae
in the study materials was unknown, a homoge-
neous pool of all 30 lysates was made and inocu-
lated with decreasing concentrations of IFUs to
enable us to compare DNA extraction methods. It
should be mentioned that the concentration of C.
pneumoniae in the dilution series was very similar,
though it is impossible to achieve identical con-
centrations. Moreover, it is not known whether
the ability of the four procedures to extract C.
pneumoniae DNA from spiked materials is the
same as their ability to extract DNA from patient
materials [12].
A multicenter study [12] demonstrated that the
sensitivity of a PCR assay does not necessarily
correspond with the ability to detect C. pneumoniae
in patient material, without a logical explanation.
In the present study, we performed one PCR assay,
and because there is no reference assay available,
one should view the results of the present study in
the light of the absence of a reference PCR assay.
Taking the limitations of the present study into
consideration, we can conclude that QIAamp is a
useful and sensitive DNA extraction method, but
further effort to optimize and standardize DNA
extraction methods is needed.
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